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Abstract
OBJECTIVE—Preconception care for women with diabetes can reduce the occurrence of adverse 
birth outcomes. We aimed to estimate the preconception care (PCC)—preventable health and cost 
burden of adverse birth outcomes associated with diagnosed and undiagnosed pregestational 
diabetes mellitus (PGDM) in the United States.
STUDY DESIGN—Among women of reproductive age (15-44 years), we estimated age- and 
race/ethnicity-specific prevalence of diagnosed and undiagnosed diabetes. We applied age and 
race/ethnicity-specific pregnancy rates, estimates of the risk reduction from PCC for 3 adverse 
birth outcomes (preterm birth, major birth defects, and perinatal mortality), and lifetime medical 
and lost productivity costs for children with those outcomes. Using a probabilistic model, we 
estimated the reduction in adverse birth outcomes and costs associated with universal PCC 
compared with no PCC among women with PGDM. We did not assess maternal outcomes and 
associated costs.
RESULTS—We estimated 2.2% of US births are to women with PGDM. Among women with 
diagnosed diabetes, universal PCC might avert 8397 (90% prediction interval [PI], 5252-11,449) 
preterm deliveries, 3725 (90% PI, 3259-4126) birth defects, and 1872 (90% PI, 1239-2415) 
perinatal deaths annually. Associated discounted lifetime costs averted for the affected cohort of 
children could be as high as $4.3 billion (90% PI, 3.4-5.1 billion) (2012 US dollars). PCC among 
women with undiagnosed diabetes could yield an additional $1.2 billion (90% PI, 951 million-1.4 
billion) in averted cost.
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CONCLUSION—Results suggest a substantial health and cost burden associated with PGDM 
that could be prevented by universal PCC, which might offset the cost of providing such care.
Keywords
diabetes mellitus; economic analysis; pregnancy complications
Women with preexisting, or pregestational, diabetes mellitus (PGDM) have increased risk of 
adverse birth outcomes.1-8 PGDM refers to women with type 1, type 2, or secondary 
diabetes before pregnancy, excluding gestational diabetes. Preconception care (PCC) for 
women with PGDM reduces the frequency of such outcomes, most likely by improving 
glycemic control before and during the critical first weeks of pregnancy.9-12 Preconception 
care refers to a range of interventions to improve women’s health before conception and 
thereby improve pregnancy-related outcomes.13,14 A recent US study reported significant 
variation in indicators within several PCC health domains, including general health status, 
health insurance status, tobacco, and alcohol use, and contraceptive use based on geographic 
location and women’s age and race/ethnicity.15 The American Diabetes Association 
recommends that PCC for women with PGDM include contraception until optimal glycemic 
control is achieved, appropriate diet and exercise, folic acid supplementation, discontinued 
use of potentially teratogenic medications, screening, and treatment for diabetic 
complications, screening for rubella immunity, and risk counseling.16 Previous studies of a 
variety of small-scale PCC interventions among women with PGDM reported that PCC 
cost-effectively improved birth outcomes.17-22
Given PCC’s proven clinical effectiveness in reducing adverse birth outcomes among 
women with PGDM, we aimed to estimate the preventable health and cost burden of adverse 
birth outcomes associated with diagnosed and undiagnosed PGDM in the United States. To 
our knowledge this is the first study to produce such estimates.
Materials and Methods
No single publicly available US dataset contains all information necessary to directly 
estimate the potential impact of identifying and treating all women with PGDM before they 
conceive. Such a dataset hypothetically would report long-term clinical data and associated 
health care payment information for women and their children, as well as laboratory results 
from pregnancy to identify previously undiagnosed PGDM.23 Given the limitations of 
available data, we compiled existing information from a variety of sources as inputs for a 
mathematical model. All model inputs are described in detail below and reported in Table 1.
Model inputs included the current population size of US women of reproductive age 
(defined as 15-44 years24), age- and race/ethnicity-specific prevalence of diagnosed and 
undiagnosed diabetes, age- and race/ethnicity-specific live birth rates, the effectiveness of 
PCC for women with PGDM (hereafter referred to simply as PCC) in terms of reducing 
adverse birth outcomes, and the associated lifetime cost of those birth outcomes. The main 
outcome measures were the total reduction in number of adverse birth outcomes and costs 
achievable for a cohort of US women of reproductive age through universal PCC compared 
with no PCC among all women with diagnosed and undiagnosed PGDM. This analysis 
Peterson et al. Page 2
Am J Obstet Gynecol. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
examined birth outcomes and costs for affected children with a lifelong time horizon from a 
societal perspective, including both discounted direct (medical and other services) and 
indirect (lost productivity) costs. We did not assess the costs of PCC or maternal outcomes 
and associated costs. This study used publicly available data, did not include human 
subjects, and was exempt from Institutional Review Board approval.
Population size and birth rate
Current population estimates of women of reproductive age were obtained from the US 
Census.25 Age- and race/ethnicity-specific live birth rates were obtained from the National 
Vital Statistics System.24 The live birth rate among women with diabetes was assumed to be 
similar to the general population.26,27
Diabetes prevalence
An estimated 2.9% (95% confidence interval [CI], 2.7–3.2) of women of reproductive age 
(defined as 18-44 years in the source publication) have diagnosed diabetes.28 This estimate 
is based on self-report among study participants in the nationally representative 2009 
Behavioral Risk Factor Surveillance System (BRFSS). Another study estimated a 0.5% 
prevalence (no measure of dispersion was reported because of limited sample size) of 
undiagnosed diabetes among US women of reproductive age (defined as 15-44 years in the 
source publication) using the nationally representative 1999-2010 National Health and 
Nutrition Examination Survey (NHANES).29 We used sex-, age-, and race/ethnicity-specific 
data on diagnosed diabetes from the BRFSS to estimate the number of women of 
reproductive age with diagnosed and undiagnosed diabetes by selected age and race/
ethnicity categories (Table 1).30
Impact of preconception care
A systematic review and meta-analysis of 12 observational cohort studies (n = 2502 
participants) examined the health impact of PCC interventions among women with 
PGDM.10 Interventions in original studies included a combination of some or all of the 
following: pharmacologic or dietary glycemic control, blood glucose monitoring, counseling 
or education on the risks of diabetes in pregnancy, screening and treatment of diabetic 
complications, and contraception until glycemic control was achieved. The metaanalysis 
reported the frequency of the following adverse birth outcomes among women with PGDM 
who did not receive PCC services: 41.4% delivered preterm (n = 155/374 women in 4 
original studies), 7.3% had children with birth defects (n = 110/1512 women in 11 original 
studies), and 4.4% had children who died in the perinatal period (n = 28/634 women in 5 
original studies). 10 Preterm deliveries were infants born before 37 weeks’ gestation; birth 
defects were not defined in the metaanalysis and the contributing studies used a variety of 
definitions. Because of overlap among outcomes in source publications (eg, a child with 
birth defects could have been born preterm), the metaanalysis did not report rates of adverse 
birth outcomes on a per-newborn basis. We are not aware of similar US studies with which 
to compare these estimates. A 1996-2004 population-based UK study of women with known 
PGDM (n = 1258 pregnancies) reported 3.7% perinatal mortality and 9.0% of live born 
children had birth defects; the preterm birth rate was not reported.31 However, no 
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information was provided on women’s PCC status or glycemic control in the UK study; 
therefore, these results are not directly comparable.
Results of the metaanalysis indicated PCC was associated with statistically significant 
reductions in preterm delivery, birth defects, and perinatal mortality (Table 1). There was no 
significant association reported between PCC and cesarean delivery, preeclampsia, 
spontaneous abortion, macrosomia, neonatal hypoglycemia, respiratory distress syndrome, 
or newborns’ small for gestational age status.10 In the metaanalysis, PCC was associated 
with a significantly higher risk of maternal hypoglycemia, although we did not evaluate 
maternal outcomes in the present study.
Lifetime cost of adverse birth outcomes
We used published estimates of the lifetime costs of preterm birth and 17 selected birth 
defects.32,33 These estimates included separately reported medical, special education, 
developmental services, and lost productivity costs for affected children. Estimated costs of 
selected individual birth defects (eg, tetralogy of Fallot, spina bifida) were reported 
separately in the source publication, and estimates did not include all types of birth 
defects.33 To estimate a general lifetime cost of birth defects, we calculated the average cost 
of individual defects weighted by the general population frequency of those defects reported 
in the source publication, which was based on California data. We estimated the lifetime 
cost of perinatal death as the value of lifetime lost household and labor market 
productivity. 34 The lifetime costs of preterm birth and perinatal mortality were calculated in 
the source publications as present values with the recommended 3% annual discount rate 
applied to costs in future years.35 To approximate this discount rate for the birth defects 
estimate, we obtained the lifetime medical-only cost of birth defects discounted at 3% from 
the source publication’s author (via personal communication, Dec. 2013), to which we 
applied the ratio of lifetime total costs to lifetime medical-only costs reported with a 5% 
discount rate in the source publication. Costs are reported as 2012 US dollars based on the 
Gross Domestic Product deflator and are reported separately as total, medical and other 
services, and lost productivity costs.36,37
Model
Among the US population of women of reproductive age (62.7 million25), we estimated the 
number with diagnosed diabetes (2.9% of the population28) and with undiagnosed diabetes 
(0.5% of the population without a diabetes diagnosis29) by age group and race/ ethnicity.30 
Among that estimated number of women with diabetes, we applied age- and race/ethnicity-
specific birth rates (eg, 109.7 births per 1000 white, nonHispanic women age 25-29, 197.1 
per 1000 Hispanic women age 25-2924). Among that estimated number of births to women 
with PGDM, we estimated the number of adverse birth outcomes in the absence of PCC 
(41.4% preterm deliveries, 7.3% children with birth defects, 4.4% perinatal deaths10). To 
estimate the PCC-preventable health burden of adverse birth outcomes associated with 
PGDM, we applied average rates of relative risk reduction associated with PCC for preterm 
birth, birth defects, and perinatal mortality estimated in the recent PCC metaanalysis.10 We 
estimated the preventable cost burden for each outcome by multiplying the estimated 
number of outcomes by their associated lifetime cost estimates.32-34
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We used probabilistic analysis to inform model inputs for which sufficient data were 
available in source publications, and we used only reported point estimates for other inputs. 
We included a Pert distribution for the prevalence of diagnosed diabetes among women of 
reproductive age based on the 95% CI that accompanied the 2.9% point estimate reported in 
the recent BRFSS study.28 We used the same distribution to test the 95% CI for relative risk 
reductions associated with PCC estimated in the recent metaanalysis.10 Using Latin 
Hypercube sampling, the number of model simulations was determined by convergence 
criteria. Simulations ceased when there was a 90% chance that the mean value of each 
simulation was within 3% of its actual value.38 We reported mean estimates and 90% 
prediction intervals (PIs)—or, the range of outcome results that included 90% of model 
simulations—for all outcome measures. We separately reported results for women with 
diagnosed and undiagnosed PGDM. We separately reported the estimated preventable cost 
burden for each adverse birth outcome in terms of direct and indirect costs, as well as the 
sum of those costs, not taking into account the overlap across outcomes. Analysis was 
conducted with @RISK software for Microsoft Excel (version 6.2; Palisade Corp, Ithaca, 
NY).
Results
Our approach estimated 2.2% of current US births occur to women with diagnosed and 
undiagnosed PGDM combined (Table 2). Among women with diagnosed diabetes who give 
birth (n = 69,357 births), universal PCC compared with no PCC might avert 8397 (90% PI, 
5252-11,449) preterm deliveries, 3725 (90% PI, 3259-4126) birth defects, and 1872 (90% 
PI, 1239-2415) perinatal deaths annually (Table 2). Among women with undiagnosed 
diabetes who give birth (n = 18,723 births), PCC might avert an additional 2267 (90% PI, 
1380-3072) preterm deliveries, 1106 (90% PI, 883-1102) birth defects, and 505 (90% PI, 
336-653) perinatal deaths annually.
The estimated PCC-preventable discounted lifetime costs among children of women with 
diagnosed PGDM were $502 million (90% PI, 314-684 million) for preterm births, $1.5 
billion (90% PI, 1.3-1.7 billion) for birth defects, and $2.3 billion (90% PI, 1.5-3.0 billion) 
for perinatal deaths, for a combined total of $4.3 billion (90% PI, 3.4-5.1 billion), not taking 
into account potential double-counting of newborns with more than 1 measured outcome 
(Table 2). The total cost included $767 million (90% PI, 611-928 million), or 18%, in direct 
medical and other costs and $3.6 billion (90% PI, 2.7-4.3 billion), or 82%, in lost 
productivity costs (Table 2). Likewise, the total PCC-preventable cost among women with 
undiagnosed PGDM was $1.2 billion (90% PI, 951 million-1.4 billion); $207 million (18%) 
in direct medical and other costs, and $963 million (82%) in lost productivity costs (Table 
2).
Comment
We estimated thousands of adverse birth outcomes might be prevented each year among US 
women with PGDM through universal PCC at an estimated lifetime societal cost savings of 
up to $5.5 billion. This study estimated the potential impact of PCC services with proven 
effectiveness. Our estimates drew on population-based age- and race/ethnicity-specific 
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PGDM prevalence data and birth rates as well as results from a metaanalysis of PCC studies. 
Our model included probabilistic elements to test a range of possible values of diagnosed 
diabetes prevalence and PCC effectiveness. We separately reported results for women with 
diagnosed and undiagnosed PGDM, and we differentiated between direct medical as well as 
other service costs and lost productivity costs. With improved availability of population-
based electronic health data, it might be possible to use large-scale, comprehensive health 
care and payment data to directly estimate the health and cost impact of PCC.
Our estimate of the proportion of US births to women with PGDM heavily influenced our 
final estimates of preventable health and cost burden. Our estimate that 2.2% of US births 
are to women with PGDM lies between 2 previous population-based estimates.27,40 One 
study of births (n = 209,287) among women enrolled in a single large managed care 
organization in California from 1999-2005 estimated 1.8% of births—adjusted for women’s 
age and race/ethnicity—were to women with diagnosed PGDM in 2005, a significant 
increase from 0.8% among the population in 1999.40 Another study estimated 3.9% of US 
births in 2013—adjusted for women’s age, but not race/ethnicity—were to women with 
diagnosed and undiagnosed PGDM. That study’s estimate was derived from a global 
systematic review of population-based studies of hyperglycemia first detected in pregnancy, 
applying new World Health Organization criteria to distinguish preexisting diabetes and 
gestational diabetes.23,27 The most recent published US birth certificate data suggests 0.7% 
of births in 2008 were to women with PGDM, based on 27 states reporting 2.7 million 
births, or 65% of births that year.41 However, birth information among states contributing to 
that estimate was not generalizable to the country as a whole because of demographic 
differences in terms of race/ethnicity, maternal age, marital status, and infant 
characteristics.41 Moreover, reporting of mothers’ preexisting diabetes on birth certificates is 
known to be incomplete.42,43
It is important to note that a substantial fraction of the total PCC-preventable burden of 
adverse birth outcomes among women with diagnosed diabetes is likely already realized 
through PCC. Some evidence suggests that up to one-half of American women with 
diagnosed PGDM may receive preconception counselling and achieve glycemic control 
before pregnancy.44,45 A 1996-2010 regional study from the UK suggested PCC attendance 
among women with PGDM (n = 2293 pregnancies) was around 40% and that compliance 
with key PCC goals such as folate consumption and adequate glycemic control because of 
pregnancy was even lower (37% and 28%, respectively).46
Much of the preventable burden among women with PGDM remains among those who do 
not receive PCC and among those with undiagnosed diabetes. However, women with 
undiagnosed diabetes may have less severe hyperglycemia and therefore have a lower risk of 
adverse birth outcomes, in which case our estimates may overstate the preventable health 
and cost burden among that group. Our estimates of preventable adverse birth outcomes 
among women with undiagnosed diabetes are speculative, inferred from PCC impact 
estimates among women with diagnosed diabetes. To prevent adverse birth outcomes among 
women with undiagnosed diabetes, diagnosis in the preconception period is needed; the first 
step would be screening women of reproductive age to identify those with undiagnosed 
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diabetes. In a future study, it would be relevant to investigate targeted biochemical screening 
for PGDM among high-risk women.
This study had a number of limitations. First, we examined only live births—excluding 
examination of the health and cost outcomes associated with spontaneous and therapeutic 
abortions—and we assumed women with PGDM have approximately general population 
fertility.26,27 Data from a 1965-2004 population-based study in Sweden suggested women 
with type 1 diabetes had only 80% of the number of births predicted based on general 
population fertility, although the birth rate among such women increased to be statistically 
indistinguishable from that of the general population beginning in the 1980s.26 Some US 
evidence suggests clinicians provide contraceptive and preconception counseling less 
frequently to women with diabetes than women without any chronic medical conditions, 
which could suggest a higher birth rate among women with PGDM than without.47-49
A second limitation is that estimates of PCC effectiveness from the recent metaanalysis 
might have been biased because of the age of contributing studies (published 1986-2006), as 
well as differences in patient characteristics such as age and smoking status among women 
who received PCC compared with those who did not in the original observational cohort 
studies.10 In particular, the metaanalysis estimate of preterm birth among women with 
PGDM without PCC, 41%, is primarily attributable to 1 contributing study. Moreover, the 
studies that contributed to the meta-analysis did not systematically control for antepartum 
care, which means the benefits of PCC from those studies could be overstated through 
confounding with other types of obstetric care. Some of the studies on which the 
metaanalysis was based are over 20 years old. The reduction in adverse birth outcomes 
associated with PCC may now be more modest because of better diabetes care, for example, 
better A1C control, and improved awareness of this issue in the population with diagnosed 
PGDM. Additional studies of the impact of PCC are needed. Areas for further investigation 
include the impact of PCC on preterm birth by gestational age and the impact on early fetal 
death.
Third, the present study consisted of a single cross-sectional analysis of all women of 
reproductive age. We lacked estimates of the annual incidence of diabetes in this cohort, 
which could have allowed us to incorporate factors such as passing time and changing 
cohort composition. Fourth, the lifetime cost of birth defects was based on older data from 1 
state, although it was the most recent available comprehensive estimate.33 A related 
limitation is that we used a general estimate of the lifetime cost of birth defects, which might 
not reflect the average cost of birth defects that occur most frequently among women with 
PGDM.50
A fifth limitation is that our analysis focused only on birth outcomes and did not include 
mothers’ health outcomes and associated costs. The cost of diabetes treatment and 
management can be substantial, although there is evidence that undiagnosed diabetes also 
incurs a substantial cost in terms of both medical care and lost productivity.51-53 One small 
study of women with type 1 diabetes found that PCC was associated with significantly fewer 
hospitalizations during pregnancy and shorter inpatient stays as well as shorter length of stay 
after delivery.22 Only one-half as many women who received PCC were hospitalized, 40% 
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vs. 80%, primarily for control of diabetes complications. The implication of these findings is 
that our estimates of the preventable burden among women with PGDM are understated 
because they do not take into account the preventable burden of excess hospital care among 
pregnant and postpartum women with PGDM. Additional studies of the impact of PCC on 
maternal outcomes are desirable.
On the other hand, our estimate of PCC-preventable cost burden could be a high-end 
estimate for 2 reasons. First, data on the frequency of adverse birth outcomes in the source 
publications did not explicitly report per-newborn outcomes; therefore, costs for children 
with multiple outcomes (eg, a child born preterm and with birth defects) were potentially 
double counted. Because a large number of perinatal deaths are associated with preterm 
birth and/or birth defects, the degree of double-counting of costs in our model is likely 
substantial. Second, input data on the lifetime costs of adverse birth outcomes were not 
mutually exclusive. For example, the lifetime cost of birth defect estimates in the source 
publication included the costs of both perinatal mortality and preterm birth among infants 
with birth defects. Similarly, the estimated lifetime cost of preterm births included the costs 
of infant mortality and some birth defects for infants born preterm. To address these issues, 
we reported estimated preventable costs separately by birth outcome. If one takes the 
estimated averted cost of just 1 outcome, such as birth defects (Table 2), there is still a 
substantial preventable health and cost burden associated with PGDM.
Delivery models for PCC services are highly varied;54 thus, it is difficult to calculate a valid 
point estimate for the cost of potential PCC interventions. Because a cost-effectiveness 
analysis of PCC would require robust PCC cost estimates, in this study we focused on 
calculating the potential health and cost benefits of PCC services as a first step toward an 
economic evaluation of PCC for women with PGDM. Further study of the cost and 
associated benefits of PCC for participating women, as well as women’s compliance with 
PCC, is needed.
The preconception period is critical for preventing adverse birth outcomes in women with 
PGDM. By some estimates nearly half of US pregnancies, including pregnancies among 
women with PGDM, are unplanned.15,55,56 Targeted blood glucose testing among women of 
reproductive age during existing physician office visits to identify women with undiagnosed 
diabetes might incur a nominal cost per woman.57 Once women’s PGDM status is known, 
information on both women’s pregnancy intent and existing birth control methods might 
assist clinicians to cost-effectively triage women to PCC services ranging from counselling 
on the risk of conception when glucose levels are elevated as part of an existing physician 
visit, to more intensive regimens such as glucose monitoring and pharmacologic control.
Because our aim was to quantify the total preventable burden of PGDM, our estimates 
implicitly assume full PCC participation once PGDM is identified. Not all women identified 
with PGDM accept glucose screening or PCC or, once begun, fully adhere to recommended 
interventions. Further, access to reproductive services is not equally distributed across the 
US female population of reproductive age; it is possible that lack of insurance coverage 
might disproportionately affect women with both unintended pregnancies and undiagnosed 
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PGDM, creating a substantial cost barrier to PCC for such women. Our estimates indicate 
the potential economic benefit of PCC if it were to be fully utilized by eligible women.
Our results suggest the PCC-preventable health and cost burden of adverse birth outcomes 
associated with PGDM is substantial. The cost of interventions to identify and provide PCC 
to women of reproductive age with diabetes could be compared with our results to assess 
how clinical and public health activities might cost-effectively address this preventable 
burden.
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